Royalty Report: Drugs, Antibody, Disease – Collection: 161645

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Antibody
  • Disease
  • Drug Discovery
  • nucleic acid
  • DNA
  • Immune
  • Therapeutic
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 161645

License Grant
Licensor, a nonprofit medical research facility, grants to Licensee an exclusive, worldwide license, without the right to sublicense, to Licensors Technology and under Licensors Patent Rights, to use the Licensed Process to make Licensed Product and to use and sell Licensed Product in the Field, provided, however, such exclusive license shall convert to a non-exclusive license either on the second anniversary of the Effective Date if Licensee has failed to sell Licensed Product prior to such anniversary or on the fifth anniversary of the Effective Date.
License Property
Licensor is engaged in fundamental scientific research including research relating to catalytic antibodies  and the expression of proteins in algae.  The Aldolase Catalytic Antibody 38C2 is an aldol addition reaction  catalyzing antibody or antibody fragment having an amino acid residue sequence equivalent to that of an aldol addition reaction catalyzing antibody or antibody fragment encoded by nucleic acid in or from hybridoma 38C2 described in U.S. Patent No. 5,733,757.  The term Licensed  Process is any process utilizing Scripps Technology to produce Aldolase Catalytic Antibody 38C2 in microalgae.
Field of Use
Licensor's patented Aldolase Catalytic Antibody 38C2 in microalgae is a genetically engineered aldolase catalytic antibody may have numerous potential applications in industrial synthesis, including the synthesis of certain anti-cancer compounds.

The Field is all applications or products except those adapted or intended for preventing,  treating,  mitigating or diagnosing a disease or condition in humans or vertebrate animals.

Licensee is engaged in the development of algal protein expression systems for the large-scale production of proteins useful in research and industrial enterprises.

IPSCIO Record ID: 280836

License Grant
Licensor, a nonprofit medical research facility, hereby grants to Licensee an exclusive, worldwide license, including the right to sublicense, under the Licensor Patent Rights and the Licensor Technology to make, to have made, to use, and to sell Licensed Products in the Field, subject to the terms of this Agreement. Promptly upon execution of this Agreement, Licensor shall provide Licensee with all information available to Licensor regarding the Licensor Patent Rights and the Licensor Technology.
License Property
The term Licensor Patent Rights shall mean (a) U.S. Patent Application Serial No. 08/210,715, entitled 'Methods and Compositions Useful for Inhibition of Angiogenesis' filed March 14, 1994, together with all foreign counterparts thereof; (b) the patents proceeding from such applications, and (c) all divisionals, continuations, continuation-in-part, reissues, renewals, reexaminations, and extensions thereof, so long as said patents have not been held invalid and/or unenforceable by a court of competent jurisdiction from which there is no appeal or, if appealable, from which no appeal has been taken. The foregoing notwithstanding, Licensor Patent Rights shall not include any claim that covers subject matter not disclosed in said United States Patent Application Serial No. 08/210,715.

The term Licensor Technology shall mean the Licensor LM609 Technology and the Licensor Angiogenesis Technology, whether or not the same is eligible for protection under the patent laws of the United States or elsewhere, and whether or not any such technology would be enforceable as a trade secret or the copying of which would be enjoined or restrained by a court as constituting unfair competition.

The terms Licensor LM609 Technology shall mean, collectively, Hybridoma LM609, LM609, LM609 Gene and  LM609 Sequence information.

The term LM609 Gene shall mean a nucleic acid encoding all or a portion of LM609.

The term LM609 shall mean the anti-avB3 integrin murine antibody produced by Hybridoma LM609 and fragments of said murine antibody.

The term LM609 Sequence Information shall mean the nucleotide sequence embodied in an LM609 Gene isolated from Hybridoma LM609 and the amino acid residue sequence information embodied in LM609.

The term Hybridoma LM609 shall mean the cell line HB 9537 deposited with the American Type Culture Collection.

The term Licensor Angiogenesis Technology shall mean so much of the technology as is proprietary to Licensor disclosed in United States Patent Application Serial No. 08/210,715, entitled 'Methods and Compositions Useful for Inhibition of Angiogenesis' filed March 14, 1994, a copy of which is attached hereto and incorporated herein by
reference.

Technology relates to a murine monoclonal antibody and the use of the antibody as an inhibitor of angiogenesis.
An angiogenesis inhibitor is a substance that inhibits the growth of new blood vessels (angiogenesis).

Field of Use
The term Field shall mean the diagnosis, prevention and treatment of any disease, states or conditions in humans, by use of any antibody or antibody fragment, but excluding the use of (a) LM609, and (b) any other non-immunoglobulin molecules except molecules conjugated to any antibody or antibody fragment, if the molecules conjugated thereto are not themselves inhibitors of alphaV-beta3 integrins.

IPSCIO Record ID: 256275

License Grant
The Licensor, of England, desires to grant to the Licensee, of Germany, a license on a non-exclusive basis of the right to use the Licensor Licensed Patents for the purpose of researching, developing and commercializing the MT201 Product and other products in respect of he EpCAM target.

For the research license, the Licensor of England grants to the Licensee of Germany a non-exclusive, worldwide license under the Licensor Licensed Patents and the Licensor Background Know-How to perform research and development activities in the Licensee Research Field.

For the commercialization license, Licensor grants a non-exclusive, worldwide license under the Licensor Licensed Patents and the Licensor Background Know-How to Exploit Licensed Products in the Licensee Licensed Field.

License Property
Licensor is the owner of rights for certain patents and know-how in the field of Antibody Phage Display.

The know-how includes a Training Manual Antibody Phage Display 2002, and, Licensor mammalian expression lgG vectors.

Licensed Product means the MT201 Product and any other product, substance or formulation arising from the EpCAM Target Program, in each case, the Development, manufacture, importation, use or sale of which would, but for the provisions of this Agreement, infringe one or more Valid Claims under the Licensor Licensed Patents, or utilizes the Licensor Background Know-How.

Field of Use
Licensees Licensed Field means the prognosis, diagnosis, prophylaxis or treatment of human diseases or conditions by modulation of the EpCAM Target.

Licensees Research Field means the identification or development of Antibody Products for the prognosis, diagnosis, prophylaxis or treatment of human diseases or conditions by modulation of the EpCAM Target.

The excluded field is the discovery, isolation, characterization, research, development, and/pr commercialization of an Antibody useful for the diagnosis, treatment and/or prevention of one or more of the following disease conditions wherein the primary scientific rationale or activity is neuronal and/or glial mechanisms of action of neuroprotection neurodegenerative conditions, diabetic neuropathy, pain, spinal cord injury, multiple sclerosis, and, stroke as a disease of the cerebrovasculature.

IPSCIO Record ID: 289177

License Grant
With this agreement, Licensee wishes Licensor to apply its technology and know-how to genetically engineer a Single-Chain Antibody.

The Licensor of Scotland agrees to grant the German Licensee under the patent rights a non-exclusive world-wide licence to the extent necessary to commercialise the Deimmunised antibody and/or the deliverables in the field.

Licensor grants for each specific Deimmunised antibody a non-exclusive licence under the patent rights to the extent necessary for worldwide commercialisation of the Deimmunised antibody derived from the specific Single-Chain Antibody sequence.

License Property
Licensor has certain proprietary technology, materials and know-how in genetic engineering of biological materials, including single-chain antibodies, relating to removal of potentially immunogenic sequences, from the variable regions of antibodies, or Delmmunisation to produce an antibody for therapeutic and/or in vivo diagnostic purposes.

Licensee is the owner of a cDNA which encodes a Single-Chain Antibody which binds to a specific antigen.

Licensor patent rights shall mean all patent applications and granted patents relevant to Deimmunization Technology.

Deimmunised antibody shall mean all genetically engineered variant(s) of the single-chain antibody  arising from the research.

Deimmunization technology shall mean the technical process applied by Licensor to generate Deimmunised antibody as outlined in the research program.

DeImmunisation increases the clinical potential of antibody and protein therapeutics by eliminating/reducing the T-cell response caused when the therapeutic molecule is recognised as foreign by the patient's immune system. The technology is based on ‘peptide threading' and works by identifying potential T-cell epitopes on the therapeutic antibody or protein. T-cell epitopes are sites on the therapeutic molecule which can bind to MHC class II, triggering a T-cell mediated immune response. Once this potentially immunogenic region of the antibody is identified, it is removed from the molecule by single amino acid substitutions, thus eliminating/reducing the therapeutic antibody or protein's immunogenicity and increasing its safety. This can be done without compromise to efficacy.

Field of Use
The field shall mean the field of human therapy and human in vivo and in vitro diagnostics limited to the Single-Chain Antibody.

IPSCIO Record ID: 227247

License Grant
Subject to Third Party rights the United Kingdom Licensor, government organization, grants to the United Kingdom Licensee during the continuance of this Agreement the following rights and licenses under the Patent Rights and the Technology on the following conditions
For the Exclusive Rights
Licensor grants the exclusive right and license under Licensee License Conditions to identify, develop, make, have made, import, market and sell selective antibodies for human in vivo use and includes using an antibody gene as a therapeutic entity in gene therapy provided always that Licensee will grant up to six exclusive sub-licenses to develop, make, have made, use, import, market and sell a specific antibody product directed at a particular antigen, for the avoidance of doubt it is declared antibodies derived from  SCID Hu mice would count within this total, to the Collaborative Centre, but excluding any right of access or license to use Licensee Libraries, with the right for the Collaborative Centre to sub-sub license for royalties payable by the Collaborative Centre to Licensee and on financial terms.

And, the exclusive right and license under Licensee License Conditions to use antibodies as part of a medical, but not a research, procedure involving in vitro selection of Rare Cell Population for therapy or diagnosis.

And, the exclusive right and license under Licensee License Conditions to provide Antibody Isolation Services for third parties.

And, the exclusive right and license under Licensee License Conditions to use and exploit commercially in any way whatsoever the inventions the subject of the patent and its corresponding patents for Diabodies except in the following fields of use
(a) biosensors;
(b) therapeutic products which include mammalian retroviruses encoding diabodies as a fusion with viral coat proteins; and
(c) diabodies generated from combinations of four specific antibodies.

And, the exclusive right and license under Licensee License Conditions to use molecules isolated by the Technology for use in the manufacturing process of pharmaceutical products or intermediates.

And, the exclusive right and license under Licensee License Conditions to develop, make, have made, use, import, market and sell Catalytic Antibodies or Research Products.

And, for Co-exclusive rights
the co-exclusive right and license for Licensee under Licensee License Conditions to improve. develop, make, have made, import, market and sell antibodies originally isolated by hybridoma derived methods from non-primate sources which have been humanized using CDR grafting techniques the subject of the patent known as Winter l, derived from the UK Patent application UK 860 7679 filed 27 March 1986-and US Parent Application 903776.

And, the co-exclusive right and license for Licensee under Licensee License Conditions to use antibody structural information to design non-antibody drug candidates.

And, for Gene-sequencing and analysis rights,  the exclusive right and license under Licensee License Conditions to use antibody repertoires and libraries and antibodies isolated from them in the identification, analysis and validation of targets for therapeutic, diagnostic or prophylactic entities arising from gene sequencing data and analysis provided always that Licensor shall have the right, which for the avoidance of doubt it is declared and agreed does not include any right of access to or license to use the Licensee Libraries, to grant collaborative licenses.

And, for the Third Party License, a non-exclusive license to third party companies who are licensed by Licensor to use and exploit other Licensor pending or granted patent rights or technology which third
parties focus and which other Licensor rights are not principally in the field of therapeutic antibodies.

And, for the non-exclusive rights,  the non exclusive right and license under Licensee License Conditions for all purposes other than those specifically excluded.

This Party agreement is, in relation to such a target, an exclusive license to develop, make, have made, market and sell only therapeutic antibodies to any such target; and, in relation to such a Product which is an actual or potential therapeutic antibody an exclusive license to develop, make, have made, market and sell only such therapeutic antibody.

License Property
Products means any product or formulation whose development, manufacture, use or sale would, absent a license, infringe the Patent Rights or utilize the Technology.

Catalytic Antibodies means antibodies which bind to and catalyze the chemical transformation of a substrate and in which an antibody binding region is involved in said catalysis.

Patents include Cloning Immunoglobulin Variable Domain Sequences; Methods for producing members of specific binding pairs; Production of chimaeric antibodies, a combinational approach; Production of anti-self antibodies from antibody segment repertoires and displayed on phage; Methods for producing members of specific binding pairs; SBP members with a chemical moiety covalently bound within the binding site production and selection thereof; Recombinant Binding Proteins and Peptides; and, Treatment of cell populations.

Field of Use
The use of the antibodies is intended for medical procedure, not research.  

The third party rights are for the field of human drug therapy by antibodies directed against the CD4-binding domain of the HIV-1 gp 120 protein.

IPSCIO Record ID: 256278

License Grant
On the Effective Date the Parties have terminated a certain Collaboration Agreement, and with this agreement, the Parties desire to reallocate the rights and responsibilities of the Parties with respect to further research and development of the GM-CSF Target.

Licensor grants to Licensee of Germany an exclusive, worldwide, license under the Licensor Licensed Technology to Exploit Licensed Products.

Licensor grants a worldwide, non-exclusive, perpetual, irrevocable and non-terminable license under the Collaboration Patents, as defined in the Collaboration Agreement, with the right to grant and authorize the grant of sublicenses, to Exploit Licensed Products.

License Property
BiTE Product means any composition or formulation consisting of or comprising a bi-specific Single Chain Antibody expressed as a single polypeptide chain, binding to T-cells.

GM-CSF Target means the whole or part of the human granulocyte macrophage-colony stimulating factor identified by the SWISS-PROT entry name CSF2 HUMAN and accession number P0414 l.

Single-Chain Antibodies
Antibodies are proteins produced by the body's immune system in response to the presence of antigens, such as bacteria, viruses or other disease causing agents. Antibodies of identical molecular structure that bind to a specific target are called monoclonal antibodies. Single-chain antibodies are genetically engineered antibodies that incorporate only the antigen binding domains of an antibody. Thus, SCAs have the binding specificity and affinity of monoclonal antibodies; however, in their native form they are only one-fifth to one-sixth the size of a monoclonal. The small size of SCAs typically gives them shorter half-lives than monoclonal antibodies, making them better suited for use in acute indications or in other indications where the large size of a monoclonal antibody would inhibit the compound from reaching the area of potential therapeutic activity. In addition, SCAs are a well-established discovery format-of-choice in generating antibodies from phage or yeast display libraries.

Field of Use
The field for Patent 5,223,409 is solely in the field of manufacture, use or sale of Single Chain Antibodies.

The field of use for this agreement otherwise is limited to not include the right to exploit the Products for Radioimmunoguided Surgery(TM), Reagents and kits in the research market for production and cloning of genes encoding Single Chain Antibodies and their fusions in a filamentous bacteriophage-derived vector system, and for expression and screening of Single Chain Antibodies fused with the minor coat protein or attachment or adsorption protein of filamentous bacteriophage, and, Single Chain Antibodies fused with, or for the assay or purification of, Tumor Necrosis l Factor alpha (TNF-a.) or Lymphotoxin.

Products for Radioimmunoguided SurgeryTM (RIGS'), in which a radiolabelled Single Chain Antibody is administered to a cancer patient; time elapses for preferential concentration of the radiolabelled Single Chain Antibody in neoplastic tissue and decrease of background radioactivity in the patient; and such preferentially concentrated radiolabelled Single Chain Antibody is detected within a surgical operative field by a detector probe placed in juxtaposition with tissue suspected of containing said radiolabelled Single Chain Antibody.

IPSCIO Record ID: 372444

License Grant
The existing agreement is for the rights to use Licensor’s antibody phage display technology.  This agreement is to extend the term  and amend other terms.

Licensee shall have rights to use and practice the Licensor Technology, and Licensor licensed Patent Rights and Know-How as follows
— For the Licensor Antibody library, Licensor grants to Licensee a world-wide, nonexclusive license, without the right to grant sublicenses, to use the Licensor Antibody Library and to practice the Licensor Patent Rights solely in connection with the use of the Licensor Antibody Library to research, develop and make Antibody Compounds and a world-wide, nonexclusive license, with the right to sublicense, to use the Antibody Compounds in order to make, have made, use, sell or import Licensed Products.

For Licensor Materials, In connection with the practice of the license rights set forth, Licensor grants to Licensee a worldwide, non-exclusive, non-transferable license, without the right to grant sublicenses, to use the Licensor Materials on its own behalf only to identify Antibody Compounds from the Licensor Antibody Library and to make quantities of Antibody Compounds that are reasonably required for research and development activities only.

For the Third Party Sublicense Rights, During the library License Term, Licensee shall have rights to use and practice the Licensor licensed Patent Rights and Know-How.

License Property
Licensor possesses intellectual property and know-how related to, among other things, the discovery of antibodies having novel binding properties using phage display.

Licensed Product means any Antibody Compound or product that incorporates an Antibody Compound, whether or not conjugated to another compound that is a Therapeutic Product or an In Vitro Diagnostic Product.

The licensed library is The phagemid-based Fab library.

Licensed materials include Expression vectors pXPlsacB and pXP2sacB for soluble Fab production in E. coli. IgG expression vectors (pBRV and pShuttle) for rapid subclomng and converting Fab fragments into human IgGl and IgG4 and munne IgG2a. (Streptavidin-binding antibody clones will be provided as a positive control.)

The patents include
— Phage display patents
— Focused libraries of genetic packages
— Novel methods of constricting libraries of human FAB antibody fragments displayed on filamentous phage
— Ligand Screening and Discovery
— Modular Assembly of Antibody Genes, Antibodies Prepared Thereby and Use
— Novel Plasmid Vector with Pectate Lyase Signal Sequence

Field of Use
The field of use is Therapeutic Field of Use means shall mean human therapeutics only and not for any in vitro or in vivo diagnostics, purification or separations, research products nor for any other purposes.

IPSCIO Record ID: 372551

License Grant
For the Grant of Licensee Product License by Licensor of the United Kingdom To Licensee, In the event Licensor notifies Licensee above that a Nominated Target has passed the Licensor Gatekeeping Procedure, then upon receipt by Licensor of the applicable Acceptance Fee, Licensor agrees to grant and hereby grants to a non-exclusive license, with the right to sublicense, under the Licensor Antibody Phage Display Patents and Licensor Know-How to Exploit Products against such Nominated Target in the Territory, the Licensee Product License.

For the Grant of Other Licenses for Other Products, Licensor grants with effect from 3 January 2003 to Licensee a non-exclusive license in the Territory, with the right to sublicense, under the Licensor Antibody Phage Display Patents and the Licensor Know How for any purpose not already covered by the provisions of this Agreement, Other Purposes, including to Exploit any product, other than a Therapeutic Antibody Product, Diagnostic Antibody Product or Research Product, whose development, manufacture, use or sale would, absent the license hereunder, infringe Valid Claims of the Licensor Antibody Phage Display Patents or utilize the Licensor Know-How, Other Product License.

License Property
Licensor is the owner or exclusive licensee of the Licensor Antibody Phage Display Patents.

Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.

Licensor Product means any preparation for the treatment or prevention of disease, infection, or other condition in humans for any indication which contains, comprises, or the process of development or manufacture of which utilizes a Licensee Licensable Antibody, or, any preparation in the form of a device, compound, kit or service with utility in the diagnosis, prognosis, prediction, or disease management of a disorder for any indication which contains, comprises or the process of development or manufacture of which utilizes a Licensee Licensable Antibody.

Diagnostic Antibody Product means any preparation in the form of a device, compound, kit or service with utility in the diagnosis, prognosis, prediction or disease management of a disorder for any indication which contains, comprises or the process of development or manufacture of which utilizes a Licensor Licensable Antibody.

Target shall mean
— a polynucleotide sequence corresponding to a sequence identified in a publicly available curated
database such as GenBank® by means of an accession number or similar sequence information
that uniquely identifies that sequence;
— a non-proteinaceous antigen that is uniquely identifiable in a routine manner using publicly
available curated databases and/or such other suitable written material as is available.

The Licensor Know-How includes
— Training Manual 'Antibody Phage Display' 2002.
— mammalian expression IgG vectors
—-pEU1 .2 (human gamma-1 heavy chain)
—-pEU3.2 (human kappa light chain)
—-pEU4.2 (human lambda light chain), and,
—-pEU8.2 (human gamma-4 heavy chain).

Field of Use
Antibody phage display is a versatile, in vitro selection technology that can be utilized to discover high affinity antibodies specific to a wide variety of antigens (94).

The Field of Use means research and development of human or non-human therapeutics and human or nonhuman in vitro diagnostic or research reagent uses only and not any in vivo diagnostics, purifications or separations, or other industrial purposes.

IPSCIO Record ID: 256276

License Grant
The Licensor of England grants to Licensee of Germany a nonexclusive, worldwide license under the Licensor Licensed Patents and the Licensor Background Know-How to Exploit Licensed Products in the Field.
License Property
Licensor is a UK-based biotechnology company using its proprietary technologies and capabilities in human monoclonal antibodies for drug discovery and drug development.

Licensed Product means any product, substance or formulation arising from the Target Program, and the Development, manufacture, importation, use or sale of which would but for the provisions of this Agreement infringe one or more Valid Claims under the Licensor Licensed Patents, or which utilizes the Licensor Background Know-How.

The know-how includes Training Manual Antibody Phage Display 2002, and, mammalian expression IgG vectors.

Field of Use
The Field means the prognosis, diagnosis, prophylaxis or treatment of human diseases or conditions by modulation of the Target. Target means the whole or part and natural variants of the granulocyte-macrophage colony stimulating factor (GM-CSF) identified by the SWISS-PROT entry name CSF2_HUMAN and accession number P04141 with the amino acid sequence which is specifically recognized by an Antibody binding to the foregoing.

Licensee obtains the right within the framework of their collaboration to use Licensor’s intellectual property in phage display to create and commercialise novel antibody products against a defined number of targets.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.